US › Healthcare

Gain Therapeutics Inc (GANX)

US · Healthcare · Biotechnology

$1.03+7.25%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.7M

EPS

$-0.11

EPS estimate

$-0.14

EPS came in at -0.11 against a street estimate of -0.14 — a beat of 21.4%.

Key statistics

Market cap

$41.9M

Forward P/E

0.0

P/B

4.44

Book value

$0.26

EPS (TTM)

$-0.50

52-week high

$4.34

52-week low

$0.94

50-day MA

$1.57

200-day MA

$1.85

Beta

0.30

Analyst view

Analysts rate Gain Therapeutics Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.20.

Shareholding

Insiders

2.23%

Institutions

19.88%

Largest institutional holders

Fund	Stake
Marshall Wace Asset Management Ltd	4.41%
CAMBRIDGE Invest RESEARCH ADVISORS, INC.	2.61%
Potomac Capital Management, Inc.	2.17%
GSA Capital Partners LLP	1.45%
JONES FINANCIAL COMPANIES LLLP	1.39%
Vanguard Capital Management, LLC	1.10%
Geode Capital Management, LLC	1.04%
BlackRock Inc	0.63%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gain Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.